Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 76 clinical trials
The Efficacy of Bendamustine, Gemcytabine, Dexamethasone Salvage Chemotherapy With Autologous Stem Cell Transplantation (BURGUND) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy (BURGUND)

The objective of the study is evaluation of efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) salvage therapy with autologus stem cell transplantation (ASCT) consolidation in advanced

cancer
bendamustine
lymphoma
classical hodgkin lymphoma
cell transplantation
  • 28 views
  • 25 Mar, 2022
  • 13 locations
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

patients responding to first salvage therapy and long-term survival of only 10%. Therefore, novel therapies for patients with relapsed/refractory T-ALL/LBL represent an unmet clinical need. Recent

  • 122 views
  • 07 Jul, 2022
  • 1 location
  • 0 views
  • 23 Mar, 2022
  • 1 location
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

In this multicenter, upfront randomized phase II trial, all patients receive quizartinib in combination with HAM (high-dose cytarabine, mitoxantrone) during salvage therapy. Efficacy is assessed

  • 0 views
  • 28 Jan, 2021
  • 1 location
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

to super-paramagnetic microbeads. Patients will be treated with salvage therapy while this ex vivo expansion is ongoing. After the simultaneous salvage therapy and ex vivo expansion, the activated

hematologic malignancy
immunosuppressive agents
cell transplantation
acute graft versus host disease
adoptive immunotherapy
  • 2 views
  • 28 May, 2022
  • 1 location
A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg Ifosfamide Carboplatin Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory classical Hodgkin lymphoma. A PET-adapted regimen of Nivo combined with ICE as first salvage therapy was

nivolumab
classical hodgkin lymphoma
cell transplantation
chemotherapy regimen
ejection fraction
  • 0 views
  • 06 Aug, 2021
  • 3 locations
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001

cancer
bendamustine
cancer chemotherapy
cell transplantation
chemotherapy regimen
  • 5 views
  • 04 Oct, 2022
  • 8 locations
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK

neutrophil count
platelet count
corticosteroids
g-csf
monoclonal antibodies
  • 0 views
  • 26 Apr, 2022
  • 1 location
Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

plus cetuximab after first line pembrolizumab failure is an effective salvage therapy in 50 R/M HNSCC patients. The primary endpoint is ORR according to RECIST V 1.1.

nivolumab
measurable disease
paclitaxel
neck cancer
head and neck cancer
  • 2 views
  • 06 Jun, 2022
  • 1 location
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

therapy approximately half of patients will develop recurrence of their cancer at the site of the original primary cancer. Salvage therapy options are largely ineffective and nearly all patients who

intensity-modulated radiation therapy
neutrophil count
paclitaxel
unresectable esophageal cancer
chemoradiotherapy
  • 4 views
  • 04 Oct, 2022
  • 1 location